GW Pharma (GWPH) Posts Q1 Loss of 9c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
May 5, 2016 7:02 AM EDT- Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome -- Initial LGS Phase 3 pivotal data expected in June -- Conference call today at 9:00 a.m. EDT, 2:00 p.m. BST -
LONDON, May 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH) (AIM: GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year... More
The Cannabis Market Reaches New Heights
May 4, 2016 2:35 PM EDTNEW YORK, May 4, 2016 /PRNewswire/ --
It is a rare opportunity when a market that is potentially worth hundreds of billions of dollars is virtually untouched by large companies. While the number of states where the growth and sales of Cannabis products remains limited, the majority of the population in the United States approves the end of federal marijuana prohibition nationwide. For now, in states where cannabis is a legitimate and legal product, sales are through the roof. Â
A recent report by New Frontier and ArcView Market Research has revealed some very impressive numbers. Sales of... More
